Literature DB >> 8387090

Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients.

.   

Abstract

OBJECTIVE: To determine the degree to which hypertension is a risk factor for macrovascular and microvascular complications in type 2 diabetes.
DESIGN: Observational prospective study.
SUBJECTS: Newly diagnosed Type 2 diabetic patients recruited into the UK Prospective Diabetes Study (n = 3648; mean age 52 years), 40% of whom were hypertensive (blood pressure > or = 160 mmHg systolic and/or > or = 90 mmHg diastolic or already being treated for hypertension). MEASUREMENTS: The incidence of fatal and non-fatal major diabetes- and hypertension-related clinical events was determined over a median of 4.6 years' follow-up. The 3-year change in prevalence of subclinical indices of macrovascular and microvascular disease was assessed, including ECG abnormalities (Minnesota coding), left ventricular hypertrophy (ECG and chest x-ray), microalbuminuria (albumin/creatinine ratio) and moderately severe retinopathy (grading of retinal photographs).
RESULTS: The hypertensive patients had (1) a greater incidence than normotensive patients of death from diabetes-related, mainly cardiovascular events (age-adjusted odds ratio 1.82) and (2) a greater incidence of diabetes-related death and major morbidity combined, including myocardial infarctions, angina, strokes and amputation (age-adjusted odds ratio 1.56). These associations were still present after allowance for other risk factors present at the time diabetes was diagnosed. The change in the prevalence of microvascular disease over 3 years was similar in both hypertensive and normotensive subjects.
CONCLUSIONS: Hypertension is a major risk factor for cardiovascular morbidity and mortality in type 2 diabetes. Comparison with other studies suggests that patients with both hypertension and diabetes have approximately four times the cardiovascular risk of non-diabetic non-hypertensive subjects. Antihypertensive therapy may provide greater benefit in this high-risk group than in the general population.

Entities:  

Mesh:

Year:  1993        PMID: 8387090     DOI: 10.1097/00004872-199303000-00013

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  49 in total

Review 1.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  The cost of diabetes Type II in Europe: the CODE-2 Study.

Authors:  M Massi-Benedetti
Journal:  Diabetologia       Date:  2002-05-24       Impact factor: 10.122

Review 3.  What should we measure in the diabetic patient and how does this respond to therapy?

Authors:  Desmond G Johnston; Stephen Robinson; Shareen Forbes
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

4.  Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography.

Authors:  Peifeng Dai; Junhua Wang; Lin Lin; Yanyan Zhang; Zhengping Wang
Journal:  Exp Ther Med       Date:  2015-06-22       Impact factor: 2.447

Review 5.  Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Wei-Xin Li; Jian-Feng Gou; Jin-Hui Tian; Xiang Yan; Lin Yang
Journal:  Curr Ther Res Clin Exp       Date:  2010-08

6.  Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study.

Authors:  Thomas Konrad; Georg Lübben; Christine Franzen
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 7.  The DASH diet and insulin sensitivity.

Authors:  Alan L Hinderliter; Michael A Babyak; Andrew Sherwood; James A Blumenthal
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

8.  Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Authors:  G Boner; M E Cooper; K McCarroll; B M Brenner; D de Zeeuw; P R Kowey; S Shahinfar; T Dickson; R S Crow; H-H Parving
Journal:  Diabetologia       Date:  2005-08-05       Impact factor: 10.122

Review 9.  Drug treatment of hypertension complicating diabetes mellitus.

Authors:  M J MacLeod; J McLay
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  Upregulation of heme oxygenase-1 combined with increased adiponectin lowers blood pressure in diabetic spontaneously hypertensive rats through a reduction in endothelial cell dysfunction, apoptosis and oxidative stress.

Authors:  Jian Cao; George Drummond; Kazuyoshi Inoue; Komal Sodhi; Xiao Ying Li; Shinji Omura
Journal:  Int J Mol Sci       Date:  2008-12-01       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.